• Cellvizio®
    • Overview
    • Education
    • Economics
    • Indications
      • Gastroenterology
        • Barrett’s Esophagus
        • Pancreatic Cysts
        • Gastric Disease
        • Inflammatory Bowel Diseases
        • Irritable Bowel Syndrome – Food Intolerance
        • Bilio-Pancreatic Strictures
        • Colorectal Lesions
      • Pulmonology
        • Lung Nodules
        • Lung Transplant
      • Urology
  • Investors
    • Overview
    • Events and Presentations
    • Financials
    • Governance
  • About Us
    • Our Story
    • Team
      • Board of Directors
      • Leadership Team
    • Join Us
    • Commercial Network
  • Newsroom
    • News
    • Events
    • Press Coverage
  • US
    • INT
    • FR
Mauna Kea Technologies Announces the Opening of the First Italian Center of Excellence for the Use of Cellvizio® to Identify and Treat Food Intolerance in Adults

Mauna Kea Technologies Announces the Opening of the First Italian Center of Excellence for the Use of Cellvizio® to Identify and Treat Food Intolerance in Adults

by Zina | Apr 2, 2024 | News

Italy becomes the third country to launch a Cellvizio Center of Excellence following the Metrodora Institute in the U.S. and several other centers in Germany  Another key milestone in a global initiative to expand centers for Cellvizio Food Intolerance programs in key...
Mauna Kea Technologies Partners with V7 to Develop Innovative AI Applications with Cellvizio

Mauna Kea Technologies Partners with V7 to Develop Innovative AI Applications with Cellvizio

by Zina | Mar 27, 2024 | News

Paris, Boston, and London, March 27, 2024 – 5:45 p.m. CET – Mauna Kea Technologies (Euronext Growth: ALMKT), inventor of Cellvizio®, the multidisciplinary probe and needle-based confocal laser endomicroscopy (p/nCLE) platform, and V7, a leading AI and data labeling...
Mauna Kea Technologies Announces the Opening of the First Italian Center of Excellence for the Use of Cellvizio® to Identify and Treat Food Intolerance in Adults

Mauna Kea Technologies Partners with Metrodora to Create First U.S. Center of Excellence for the Use of Cellvizio® to Identify and Treat Food Intolerance in Adults

by Zina | Mar 6, 2024 | News

Cellvizio Food Intolerance Test (C-FIT) delivers real-time, in vivo visibility to accurately identify food intolerance in patients suffering from Irritable Bowel Syndrome (IBS) Metrodora will serve as Center of Excellence for patient care and physician training to...
Mauna Kea Technologies Announces the Opening of the First Italian Center of Excellence for the Use of Cellvizio® to Identify and Treat Food Intolerance in Adults

Mauna Kea Technologies Welcomes Benoit Chardon as Senior Advisor to Scale its Irritable Bowel Syndrome and Food Intolerance Business

by Zina | Feb 7, 2024 | News

Mr. Chardon is a recognized commercialization expert with a successful track record in new category creation in the health & wellness industry  Paris and Boston, February 7, 2024 – 5:45 p.m. CET – Mauna Kea Technologies (Euronext Growth: ALMKT), inventor of...
Mauna Kea Technologies Partners with V7 to Develop Innovative AI Applications with Cellvizio

Mauna Kea Technologies Announces Initiation of Coverage by EuroLand Corporate

by Zina | Feb 1, 2024 | News

Paris and Boston, February 1, 2024 – 5:45 p.m. CET – Mauna Kea Technologies (Euronext Growth: ALMKT), inventor of Cellvizio®, the multidisciplinary probe and needle-based confocal laser endomicroscopy (p/nCLE) platform, today announces initiation of coverage by...
« Older Entries
Next Entries »

Articles récents

  • Mauna Kea Technologies Announces Major AI Breakthrough with Cellvizio in Pancreatic Cystic Lesion Risk Stratification 
  • Mauna Kea Technologies Provides Update on Safeguard Proceedings, Strategic Discussions and Operational Progress 
  • Mauna Kea Technologies announces the availability of preparatory documents for the Combined General Meeting of June 5, 2025 and the instructions for participation 
  • Mauna Kea Technologies Announces Largest Annual Pancreatic Cyst Consortium at Digestive Disease Week® 2025 
  • Publication of the 2024 Annual Financial Report 

Commentaires récents

No comments to show.

Company Info

About Us

Join Us

Contact Us

Legal

Legal notice

Privacy policy

Our websites

Cellvizio.net

cell-tolerance.com

Diagnosingbarretts.org

Diagnosingpancreaticcysts.org

Follow us

  • Follow
  • Follow
  • Follow
  • Follow
Manage Consent
To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Functional Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
Manage options Manage services Manage {vendor_count} vendors Read more about these purposes
View preferences
{title} {title} {title}